1. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-1129. PMID:
16187769.
2. Hong J, Windmeijer F, Novick D, Haro JM, Brown J. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:835-841. PMID:
19351551.
3. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-1370. PMID:
17601495.
4. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-161. PMID:
17092691.
5. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-130. PMID:
17466492.
6. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-829. PMID:
18466043.
7. Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-356. PMID:
18854723.
8. Canuso CM, Youssef EA, Bossie CA, Turkoz I, Schreiner A, Simpson GM. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-215. PMID:
18545059.
9. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010;70:1295-1317. PMID:
20568835.
10. Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol 2012;8:873-888. PMID:
22632481.
11. Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008;36:769-779. PMID:
18227146.
12. Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 1993;16:313-338. PMID:
8101371.
13. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003;160:2063-2065. PMID:
14594760.
14. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry 2006;67:1707-1712. PMID:
17196049.
15. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102:230-240. PMID:
18423985.
16. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010;35:581-590. PMID:
19890258.
17. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007;68:1522-1527. PMID:
17960966.
18. Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 2007;41:659-666. PMID:
16797591.
19. Levine SZ, Leucht S. Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry 2010;68:86-92. PMID:
20227681.
20. Hatta K, Nakamura H, Matsuzaki I. Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients. Gen Hosp Psychiatry 2003;25:39-45. PMID:
12583927.
21. Kim SW, Yoon JS, Kim YS, Ahn YM, Kim CE, Go HJ, et al. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:228-235. PMID:
22516251.
22. Moon YS, Na KS, Kim CE, Kim YS, Yoon JS, Ahn YM, et al. Efficacy and safety of paliperidone extended release in schizophrenia patients requiring a switch in antipsychotic medication by switching previous antipsychotics to paliperidone extended release. Korean J Psychopharmacol 2012;23:97-106.
23. Lee JS, Ahn JH, Lee JI, Kim JH, Jung I, Lee CU, et al. Dose pattern and effectiveness of paliperidone extended-release tablets in patients With schizophrenia. Clin Neuropharmacol 2011;34:186-190. PMID:
21725234.
24. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatr Scand 1977;55:299-308. PMID:
855676.
25. Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;(416):16-23. PMID:
12755850.
26. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-329. PMID:
10782554.
27. Lee JG, Seok JH, Lee JY, Lee KU, Kwak KH, Kwon JS, et al. A validation study of the Korean-version of the personal and social performance scale. Korean J Psychopharmacol 2006;17:497-506.
28. Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D, et al. Reliability, validity and ability to detect change of the clinician-rated personal and social performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009;25:325-338. PMID:
19192977.
29. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002;57:227-238. PMID:
12223254.
30. Chang YC, Lane HY, Yang KH, Huang CL. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006;26:554-559. PMID:
17110810.
31. Schennach-Wolff R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, et al. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. J Psychiatr Res 2011;45:1639-1647. PMID:
21862035.
32. Stauffer V, Case M, Kollack-Walker S, Ascher-Svanum H, Ball T, Kapur S, Kinon BJ. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res 2011;130:11-19. PMID:
21489754.
33. Levine SZ, Rabinowitz J, Faries D, Lawson AH, Ascher-Svanum H. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012;137:141-146. PMID:
22316567.
34. Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, et al. Response trajectories in "real-world" naturalistically treated schizophrenia patients. Schizophr Res 2012;139:218-224. PMID:
22658528.
35. Collier DA. Pharmacogenetics in psychosis. Drug News Perspect 2003;16:159-165. PMID:
12819814.
36. Räsänen P, Tiihonen J, Isohanni M, Rantakallio P, Lehtonen J, Moring J. Schizophrenia, alcohol abuse, and violent behavior: a 26-year follow-up study of an unselected birth cohort. Schizophr Bull 1998;24:437-441. PMID:
9718635.
37. Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA 2009;301:2016-2023. PMID:
19454640.
38. Jones RM, Lichtenstein P, Grann M, Långström N, Fazel S. Alcohol use disorders in schizophrenia: a national cohort study of 12,653 patients. J Clin Psychiatry 2011;72:775-779. PMID:
21733478.
39. Palao DJ, Arauxo A, Brunet M, Marquez M, Bernardo M, Ferrer J, et al. Positive versus negative symptoms in schizophrenia: response to haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:155-164. PMID:
8115670.
40. Robinson DG, Woerner MG, Alvir JMJ, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from the first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549. PMID:
10200732.
41. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239-246. PMID:
1671741.
42. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991;48:978-986. PMID:
1747021.
43. Mayerhoff DI, Loebel AD, Alvir JML, Szymanski SR, Geisler SH, Borenstein M, et al. The deficit state in first-episode schizophrenia. Am J Psychiatry 1994;151:1417-1422. PMID:
8092335.
44. McGlashan TH. The prediction of outcome in chronic schizophrenia. IV. The Chestnut Lodge follow-up study. Arch Gen Psychiatry 1986;43:167-176. PMID:
3947211.
45. Johnstone EC, Macmillian JF, Frith CD, Benn DK, Crow TJ. Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 1990;157:182-189. PMID:
2224368.
46. Amminger GP, Resch F, Mutschlechner R, Friedrich MH, Ernst E. Premorbid adjustment and remission of positive symptoms in first-episode of psychosis. Eur Child Adolesc Psychiatry 1997;6:212-218. PMID:
9443000.
47. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO. Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;45:1-9. PMID:
10978867.
48. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18-24. PMID:
15231551.
49. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006;10:131-148. PMID:
17062375.
50. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, et al. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr Res 2010;118:211-217. PMID:
20189773.
51. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011;168:1303-1310. PMID:
22193673.
52. Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response? Eur Neuropsychopharmacol 2011;21:370-378. PMID:
21255982.